FDA authorises Covid antibody treatment for those at risk of severe illness
Agency stipulates treatment not substitute for vaccines
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The US Food and Drug Administration (FDA) has approved emergency use of a preventive monoclonal antibody treatment to protect those who are vulnerable to coronavirus.
The agency said in a press release last week that it had authorised the emergency use of REGEN-COV in adults and pediatric individuals who are at high risk for progression to severe Covid-19.
The antibody is only permitted to be used only after exposure to the virus and is said to be the first time an injectable antibody treatment has been approved for the prevention of Covid-19 post-exposure.
It should also only be used on those who are not fully vaccinated or may not have an “adequate immune response” to shots or those who are at high risk of exposure due to their settings, such as those in a nursing home or prison.
The FDA stipulated that the treatment is not a substitute for vaccination against Covid-19 and continued to urge people to get vaccinated if they are eligible.
NBC News reports that an estimated three per cent of Americans are immunocompromised, including those who have autoimmune diseases, cancer or are affected by HIV.
Dr Myron Cohen, a leading coronavirus antibody researcher at the University of North Carolina at Chapel Hill, explained to NBC News that the treatment works by attacking the infection before it bypasses the nose and throat.
“It’s a race between your ability to make an antibody to protect your lungs and the rest of your body and the virus,” he told the broadcaster.
He added: “And if you’re likely to lose the race, you’re the person for whom these antibody drugs are appropriate.”
Dr Ghady Haidar, a transplant infectious diseases physician at the University of Pittsburgh Medical Center told the outlet that “it’s good to know that” treatments are available for those who don’t respond well to vaccines.
“We can now help protect them against getting infected with SARS-CoV-2 by giving them antibodies following exposure,” she said.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments